Cargando…
BRAF Gene and Melanoma: Back to the Future
As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely re...
Autores principales: | Ottaviano, Margaret, Giunta, Emilio Francesco, Tortora, Marianna, Curvietto, Marcello, Attademo, Laura, Bosso, Davide, Cardalesi, Cinzia, Rosanova, Mario, De Placido, Pietro, Pietroluongo, Erica, Riccio, Vittorio, Mucci, Brigitta, Parola, Sara, Vitale, Maria Grazia, Palmieri, Giovannella, Daniele, Bruno, Simeone, Ester |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037827/ https://www.ncbi.nlm.nih.gov/pubmed/33801689 http://dx.doi.org/10.3390/ijms22073474 |
Ejemplares similares
-
Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas
por: Ottaviano, Margaret, et al.
Publicado: (2022) -
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
por: Ottaviano, Margaret, et al.
Publicado: (2021) -
Epigenetic Regulation in Melanoma: Facts and Hopes
por: Giunta, Emilio Francesco, et al.
Publicado: (2021) -
Mediastinal soft tissue sarcoma: dark sides and future lights
por: Palmieri, Giovannella, et al.
Publicado: (2020) -
Immunological signature of patients with thymic epithelial tumors and Good syndrome
por: Malfitano, Anna Maria, et al.
Publicado: (2022)